Related Experiment Video
Updated: Jun 4, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The need for novel anticoagulation therapy in acute coronary syndrome
Suraj Chandrasekar1, Rohit Loomba, Parinda Shah
1Chicago Medical School,North Chicago, IL, USA.
Insights
New factor Xa inhibitors offer effective anticoagulation for acute coronary syndrome (ACS) with fewer side effects and easier oral administration compared to traditional treatments like heparin and warfarin.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Acute coronary syndrome (ACS) prevalence is increasing, necessitating improved anticoagulation strategies.
- Current anticoagulants like heparin and warfarin have limitations, including significant side effects and administration challenges.
- A rising need exists for novel anticoagulants with better safety and convenience profiles.
Purpose of the Study:
- To explore the role of new factor Xa inhibitors in managing patients with acute coronary syndrome (ACS).
- To evaluate the efficacy and safety of factor Xa inhibitors as alternatives to traditional anticoagulants in ACS.
Main Methods:
- Conducted an electronic literature search using Medline and Cochrane Library.
- Included reviews, randomized controlled trials, and other relevant studies focusing on factor Xa inhibitors in ACS.
- Assessed selected studies for quality and relevance before analysis.
Main Results:
- Factor Xa inhibitors demonstrate anticoagulation efficacy comparable or superior to heparin and warfarin.
- These novel agents present lower risks of bleeding and adverse effects, including heparin-induced thrombocytopenia.
- Many factor Xa inhibitors are available in oral formulations, enhancing patient compliance and daily management.
Conclusions:
- Factor Xa inhibitors represent a promising therapeutic option for anticoagulation in ACS.
- Their oral availability and improved safety profile offer significant advantages over existing treatments.
- These agents address the shortcomings of current anticoagulation regimens, meeting the growing clinical need.
Abstract:
As acute coronary syndrome (ACS) becomes more common nationwide and current anticoagulation regimens used in patients with ACS continue to possess their shortcomings, the need for new anticoagulants is on the rise. Although heparin and warfarin are used effectively in patients with ACS, they both have significant side effects and delivery issues. New factor Xa inhibitors offer an oral alternative that functions early in the coagulation cascade. The role of these new drugs in ACS is explored here. Electronic search strategies were used to collect reviews, randomized controlled trials, and other studies. Databases used included Medline and Cochrane Library and hand selection. Sources selected were limited to those that discussed factor Xa inhibitors in the context of ACS. Selected studies were then assessed for quality and relevance and those deemed relevant included for analysis. Some of the factor Xa inhibitors such as rivaroxaban offer anticoagulation as effective as, if not more effective, heparin and warfarin with lower risks of bleeding and other adverse effects such as heparin-induced thrombocytopenia. Many of these new agents also come in oral form, making them easy for patients to manage and use daily.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome III: Diagnostic Studies